Related Experiment Videos
PD treatment for severe congestive heart failure
B G Stegmayr1, R Banga, L Lundberg
1Department of Internal Medicine, University Hospital, Umeå, Sweden.
Summary
Peritoneal dialysis (PD) offers a survival benefit for patients with severe, drug-resistant congestive heart failure (sHF). This treatment reduced heart size and improved quality of life, prolonging lifespan in refractory heart failure patients.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Severe congestive heart failure (sHF) refractory to conventional medical therapy presents a significant clinical challenge.
- Patients with advanced heart failure often have limited treatment options and a poor prognosis.
Purpose of the Study:
- To evaluate the efficacy of peritoneal dialysis (PD) in improving survival and quality of life for patients with severe, drug-resistant congestive heart failure (sHF).
Main Methods:
- The study included 16 patients with NYHA class III or IV sHF unresponsive to diuretics and ACE inhibitors.
- Tenckhoff catheters were inserted for ultrafiltration, with survival time and heart size changes analyzed.
- Patients were selected by cardiologists and nephrologists, including those with and without uremia.
Main Results:
- All patients showed improvement in heart failure classification within the first month.
- Heart size was reduced in 15 patients, and 10 patients survived a median of 10 months.
- Six patients died from cardiac causes after a mean of 10.7 months; three patients without uremia discontinued PD.
Conclusions:
- Peritoneal dialysis (PD) is a viable ultrafiltration strategy for severe, refractory congestive heart failure (sHF), even with low blood pressure.
- PD can reduce heart failure severity, prolong survival, and enhance the quality of life in selected patients.
- This approach offers a potential therapeutic option for end-stage heart failure patients unresponsive to standard treatments.